AR009805A1 - Peptidos que contienen cisteina - Google Patents

Peptidos que contienen cisteina

Info

Publication number
AR009805A1
AR009805A1 ARP970104369A ARP970104369A AR009805A1 AR 009805 A1 AR009805 A1 AR 009805A1 AR P970104369 A ARP970104369 A AR P970104369A AR P970104369 A ARP970104369 A AR P970104369A AR 009805 A1 AR009805 A1 AR 009805A1
Authority
AR
Argentina
Prior art keywords
pro
proline
side chains
amino acid
glu
Prior art date
Application number
ARP970104369A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR009805A1 publication Critical patent/AR009805A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1005Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1021Tetrapeptides with the first amino acid being acidic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un péptido fisiologicamente activo de formula (I): A-(R1)x-R2-Cys-R3-B, en la cual cada A se selecciona independientemente entre H, un grupo protector, opor lo menos un residuo aminoácido seleccionado independientemente entre el grupo de residuos aminoácidos que tienen cadenas laterales alifáticas, cadenaslaterales oxhidrilo alifáticas, cadenas laterales básicas, cadenas laterales acídicas, grupos amino secundario, cadenas laterales amida, cadenas lateralesaromáticas y cadenas lateralescon contenido de azufre; x es 0 (estando ausente R1) y R2 y R3 son residuos de aminoácidos seleccionados entre una de lassiguientes combinaciones (a) y (b) de aminoácidos: (a) R2 leucina (Leu), R3 fenilalanina (Phe); (b) R2 glutamina (Gln), R3 alanina (Ala), o x es 1, y R1,y R2 y R3 son residuos de aminoácidos elegidos entre una de las siguientes combinaciones (c) y (f) a (s) de aminoácidos: (c) R1 ácido glutámico (Glu), R2prolina (Pro), R3 metionina (Met); (f) R1 alanina (Ala), R2 prolina (Pro), R3 metionina (Met); (g) R1 ácido glutámico (Glu), R2 prolina (Pro), R3 triptofano(Trp); (h) R1 serina (Ser), R2 prolina (Pro), R3 triptofano (Trp), (i) R1 leucina (Leu), R2 leucina (Leu), R3 glicina (Gly); (j) R1 prolina (Pro), R2arginina (Arg), R3 arginina (Arg); (k) R1 glicina (Gly), R2 tirosina (Tyr), R3 prolina (Pro); (l) R1 valina (Val), R2 valina (Val), R3 asparagina (Asn); (m)R1 alanina (Ala), R2 leucina (Leu), R3 arginina (Arg); (n) R1 glicina (Gly), R2 alanina (Ala),R3 prolina (Pro); (o) R1 lisina (Lys), R2 serina (Ser), R3lisina (Lys); (p) R1 ácido glutámico (Glu), R2 (Pro), R3 fenilalanina (Phe); (q) R1 ácido glutámico (Glu), R2 prolina (Pro), R3 tirosina (Tyr); (r) R1serina (Ser), R2 prolina (Pro), R3 metionina (Met); (s) R1 glicina (Gly), R2 prolina (Pro), R3 triptofano (Trp); con las condiciones de que, cuando x es O
ARP970104369A 1996-09-23 1997-09-23 Peptidos que contienen cisteina AR009805A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9603466A SE9603466D0 (sv) 1996-09-23 1996-09-23 New compounds

Publications (1)

Publication Number Publication Date
AR009805A1 true AR009805A1 (es) 2000-05-03

Family

ID=20403988

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970104369A AR009805A1 (es) 1996-09-23 1997-09-23 Peptidos que contienen cisteina

Country Status (5)

Country Link
AR (1) AR009805A1 (es)
AU (1) AU4406197A (es)
SE (1) SE9603466D0 (es)
WO (1) WO1998012213A2 (es)
ZA (1) ZA978477B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4674231B2 (ja) 2004-03-01 2011-04-20 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 2量体小分子アポトーシス増強剤
MX2009010667A (es) * 2007-04-12 2010-02-24 Joyant Pharmaceuticals Inc Dimeros y trimeros mimeticos de smac utiles como agentes anti-cancer.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0142387A1 (en) * 1983-08-26 1985-05-22 Anda Biologicals Process for the preparation of vaccines specific for LH and HCG and process for their detection
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
ES2142867T3 (es) * 1992-04-13 2000-05-01 Oklahoma Med Res Found Procedimientos y reactivos para el diagnostico de autoanticuerpos.
CA2144180A1 (en) * 1992-09-08 1994-03-17 George A. Heavner Peptide inhibitors of cellular adhesion
SE9403526D0 (sv) * 1994-10-14 1994-10-14 Astra Ab New Peptides
WO1996013589A1 (en) * 1994-10-27 1996-05-09 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from ambrosia artemisiifolia
EP0923604A1 (en) * 1996-04-12 1999-06-23 Astra Aktiebolag Cysteine-containing or methioine-containing peptides with immunomodulatory effects

Also Published As

Publication number Publication date
ZA978477B (en) 1998-03-23
SE9603466D0 (sv) 1996-09-23
WO1998012213A2 (en) 1998-03-26
WO1998012213A3 (en) 1998-04-30
AU4406197A (en) 1998-04-14

Similar Documents

Publication Publication Date Title
DE68928321D1 (de) Antiaggregative Peptide
TW343198B (en) Cyclopeptides useful as adhesion inhibitors, process for the preparation thereof, and pharmaceutical composition containing them
HUP9903530A2 (hu) Új antiangiogén peptidek,azokat kódoló polinukleotidok és eljárások angiogenezis gátlására
KR850007801A (ko) 폴리펩타이드의 제조방법
JP2006525288A5 (es)
NL300013I1 (nl) Nieuwe protein met TNF-remmende werking en hun ber
AU5019093A (en) Peptidyl activated ketone inhibitors containing natural and unnatural peptide sequences
ES2123635T3 (es) Nuevo inhibidor de la proteasa humana de tipo kunitz y sus variantes.
NZ333606A (en) Isolated peptides derived from MAGE-2
DE69723812D1 (de) Aminosäurezusammensetzungen
ES2054365T3 (es) Inhibicion de la via de la regla del n final en celulas vivas.
CY1112839T1 (el) Πεπτιδια χ-κωνοτοξινες που εχουν ενα αμινοτελικο πυρογλουταμικο οξυ
AR009807A1 (es) Peptidos que contienen analogos de cisteina.
JPS5594934A (en) Peptide type polymer and pharmaceutic composition containing it
AR009805A1 (es) Peptidos que contienen cisteina
ATE42308T1 (de) Pharmakologisch aktive peptide.
DE3751398D1 (de) Substrat-Peptide.
ATE30919T1 (de) Magensekretion hemmende peptidderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel.
STEWART Protection of the hydroxyl group in peptide synthesis
DE3782880D1 (de) Hemmende peptide.
NO931745L (no) Stabiliserte, sterkt virkende grf-analoger